Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Age-Related Macular Degeneration
In brief
This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.
Key facts
- Study ID
- NCT05893537
- Run by
- Cognition Therapeutics
- People needed
- 100
- Starts
- 2023-06-16
- Expected to finish
- 2025-03-28
- Last updated by the study team
- 2025-04-16
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥50 years at time of informed consent.
- BCVA of 24 letters or better using Early Treatment Diabetic Retinopathy Study (ETDRS) charts at screening.
- Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening.
You may not qualify if…
- GA due to causes other than dry AMD.
- Any history or current evidence of exudative ("wet") AMD.
- Retinal disease other than dry AMD.
- Any ophthalmologic condition that prevents adequate imaging of the retina as judged by the study site or central reading center.
- Intraocular surgery (including intraocular lens implantation surgery) within 3 months prior to randomization.
- Any ophthalmic condition that will or is likely to require surgery during the study period.
- Hypersensitivity to fluorescein.
- Suspected or known allergy to any components of the study treatments.
- History of vitrectomy surgery, submacular surgery or any other surgical intervention for dry AMD.
- History of glaucoma filtering surgery or corneal transplant in the study eye.
- History of central serous retinopathy in either eye.
Where it is running
- Phoenix Retina Associates — Phoenix, Arizona, United States
- Retinal Consultants Medical Group — Sacramento, California, United States
- Bay Area Retina Associates — Walnut Creek, California, United States
- Advanced Research — Deerfield Beach, Florida, United States
- Rand Eye Institute — Deerfield Beach, Florida, United States
- National Ophthalmic Research Institute — Fort Myers, Florida, United States
- Center for Retina and Macular Disease — Winter Haven, Florida, United States
- Retina Specialists — Baltimore, Maryland, United States
- Ophthalmic Consultants of Boston — Boston, Massachusetts, United States
- NJ Retina — Edison, New Jersey, United States
- Long Island Vitreoretinal Consultants — Great Neck, New York, United States
- North Carolina Retina Associates — Wake Forest, North Carolina, United States
- Verum Research LLC — Eugene, Oregon, United States
- Erie Retina Research, LLC — Erie, Pennsylvania, United States
- Tennessee Retina, PC — Nashville, Tennessee, United States
- Austin Clinical Research, LLC — Austin, Texas, United States
- Star Vision Consultants — Burleson, Texas, United States
- Texas Retina Associates — Fort Worth, Texas, United States
- Retina Consultants of Texas — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.